+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Opsumit"

Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029) - Product Thumbnail Image

Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

  • Report
  • November 2023
  • 250 Pages
  • Global
From
Pulmonary Arterial Hypertension (PAH) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030 - Product Thumbnail Image

Pulmonary Arterial Hypertension (PAH) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

  • Report
  • August 2022
  • 115 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • January 2024
  • 250 Pages
  • Global
From
Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • January 2024
  • 250 Pages
  • Global
Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Opsumit - Product Thumbnail Image

Opsumit

  • Report
  • October 2018
  • 19 Pages
  • Global
From
Adempas - Product Thumbnail Image

Adempas

  • Report
  • October 2018
  • 20 Pages
  • Global
From
Opsumit - API Insight, 2022 - Product Thumbnail Image

Opsumit - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Opsumit is a brand of cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a type of endothelin receptor antagonist (ERA) that works by blocking the action of endothelin, a substance in the body that can cause the blood vessels in the lungs to narrow. This narrowing can lead to high blood pressure in the lungs, which can cause shortness of breath, fatigue, and other symptoms. Opsumit is used to reduce the symptoms of PAH and improve exercise capacity. Opsumit is available in tablet form and is taken once daily. It is usually taken with food and should be taken at the same time each day. Common side effects of Opsumit include headache, nausea, and dizziness. The Opsumit market is a competitive one, with several companies offering similar drugs. These include Actelion Pharmaceuticals, Gilead Sciences, and United Therapeutics. Each company has its own unique formulation of the drug, and they all compete for market share. Show Less Read more